Overview Pegcetacoplan Long Term Safety and Efficacy Extension Study Status: Active, not recruiting Trial end date: 2022-08-20 Target enrollment: Participant gender: Summary This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study. Phase: Phase 3 Details Lead Sponsor: Apellis Pharmaceuticals, Inc.